Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

COMMENTED

Diabetes - GeneralType 2 DiabetesGlycemic Control

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

Diabetes Care.

Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frias J, Roussel R, Bolli GB

doi: 10.2337/dc18-0559.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

JAMA.

Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P

doi: 10.1001/jama.2017.7117.

COMMENTED

Type 2 Diabetes

Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7)

Diabetes Obes Metab.

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB, DEVOTE Study Group

doi: 10.1111/dom.13699.

Type 2 Diabetes

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2

Diabetes Obes Metab.

Heller SR, DeVries JH, Wysham C, Hansen CT, Hansen MV, Frier BM

doi: 10.1111/dom.13708.

Glycemic Control

GlucoTab guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalised patients with type 2 diabetes

Diabetes Obes Metab.

Aberer F, Lichtenegger KM, Smajic E, Donsa K, Malle O, Samonigg J, Höll B, Beck P, Pieber TR, Plank J, Mader JK

doi: 10.1111/dom.13559.

COMMENTED

Diabetes - GeneralType 1 DiabetesType 2 DiabetesGlycemic Control

Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia

doi: 10.1007/s00125-017-4449-2.

COMMENTED

Type 2 Diabetes

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Lancet Diabetes Endocrinol.

Aroda VR, González-Galvez G, Grøn R, Halladin N, Haluzík M, Jermendy G, Kok A, Őrsy P, Sabbah M, Sesti G, Silver R

doi: 10.1016/S2213-

Type 2 Diabetes

Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes

Diabetes Obes Metab.

Philis-Tsimikas A, Billings LK, Busch R, Morales Portillo C, Sahay R, Halladin N, Eggert S, Begtrup K, Harris S

doi: 10.1111/dom.13666.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Lancet Diabetes Endocrinol.

Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH

doi: 10.1016/S2213-8587(17)

Related content

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2

GlucoTab guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalised patients with type 2 diabetes

Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial